体成分与蒽环类及紫杉类化疗依从性及非转移性乳腺癌生存的关联
该观察性队列研究纳入1395例非转移性乳腺癌患者,评估诊断时CT测量的体成分与蒽环类和紫杉类化疗相对剂量强度(RDI)及血液学毒性的关联。发现内脏和肌肉内脂肪增加与RDI<0.85风险升高相关,肌肉量较高与血液学毒性风险降低相关;RDI<0.85与死亡风险增加30%相关,且低RDI部分介导了肥胖与乳腺癌特异性死亡率的关联。
要点
- 内脏脂肪每增加1个标准差,RDI<0.85的比值比为1.19(95%CI 1.02-1.39)。
- 肌肉量每增加1个标准差,血液学毒性比值比为0.84(95%CI 0.71-0.98)。
- RDI<0.85与死亡风险增加30%相关(HR 1.30,95%CI 1.02-1.65)。
核心结论
- 内脏或肌肉内脂肪过多与较低的RDI相关,低RDI部分介导了肥胖与较差的乳腺癌特异性生存之间的关联。
主要发现
- 内脏脂肪(OR 1.19;95%CI 1.02-1.39 每标准差)和肌肉内脂肪(OR 1.16;95%CI 1.01-1.34 每标准差)增加与RDI<0.85的 odds 增加相关。
- 肌肉量增加与血液学毒性 odds 降低相关(OR 0.84;95%CI 0.71-0.98 每标准差)。
- RDI<0.85与死亡风险增加30%相关(HR 1.30;95%CI 1.02-1.65)。
- 低RDI部分解释了肥胖与乳腺癌特异性死亡率的关联(中介比例0.20;95%CI 0.05-0.55)。
临床怎么用
- 体成分可能有助于识别可能发生毒性反应及后续剂量延迟或减量的患者,从而可能影响化疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although most chemotherapies are dosed on body surface area or weight, body composition (ie, the amount and distribution of muscle and adipose tissues) is thought to be associated with chemotherapy tolerance and adherence. OBJECTIVES: To evaluate whether body composition is associated with relative dose intensity (RDI) on anthracycline and taxane-based chemotherapy or hematologic toxic effects and whether lower RDI mediates the association of adiposity with mortality. DESIGN, SETTING, AND PARTICIPANTS: An observational cohort study with prospectively collected electronic medical record data was conducted at Kaiser Permanente Northern California, a multicenter, community oncology setting within an integrated health care delivery system. Participants included 1395 patients with nonmetastatic breast cancer diagnosed between January 1, 2005, and December 31, 2013, and treated with anthracycline and taxane-based chemotherapy. Data analysis was performed between February 25 and September 4, 2019. EXPOSURES: Intramuscular, visceral, and subcutaneous adiposity as well as skeletal muscle were evaluated from clinically acquired computed tomographic scans at diagnosis. MAIN OUTCOMES AND MEASURES: The primary outcome was low RDI (<0.85), which is the ratio of delivered to planned chemotherapy dose, derived from infusion records; in addition, hematologic toxic effects were defined based on laboratory test values. To evaluate associations with overall and breast cancer-specific mortality, logistic regression models adjusted for age and body surface area were fit as well as Cox proportional hazards models adjusted for age, race/ethnicity, adiposity, Charlson comorbidity index score, and tumor stage and subtype. The mediation proportion was computed using the difference method. RESULTS: The mean (SD) age at diagnosis of the 1395 women included in the study was 52.8 (10.2) years. Greater visceral (odds ratio [OR], 1.19; 95% CI, 1.02-1.39 per SD) and intramuscular (OR, 1.16; 95% CI, 1.01-1.34 per SD) adiposity were associated with increased odds of RDI less than 0.85. Greater muscle mass was associated with a decreased odds of hematologic toxic effects (OR, 0.84; 95% CI, 0.71-0.98 per SD). Relative dose intensity less than 0.85 was associated with a 30% increased risk of death (hazard ratio, 1.30; 95% CI, 1.02-1.65). Lower RDI partially explained the association of adiposity with breast cancer-specific mortality (mediation proportion, 0.20; 95% CI, 0.05-0.55). CONCLUSIONS AND RELEVANCE: Excess adiposity, presenting as larger visceral or intramuscular adiposity, was associated with lower RDI. Lower RDI partially mediated the association of adiposity with worse breast cancer-specific survival. Body composition may help to identify patients likely to experience toxic effects and subsequent dose delays or reductions, which could compromise chemotherapeutic efficacy.
引用
- Cespedes Feliciano EM, Chen WY, Lee V, et al. Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer. JAMA Oncol. 2020. PMID: 31804676. doi:10.1001/jamaoncol.2019.4668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。